Wall Street analyst estimates for GeneDx Holdings Corp. (WGS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-27 | $0.07 | ||
| 2026-08-03 | $0.01 | $-0.19 | +105.3% |
| 2026-05-04 | $-0.28 | $-0.06 | -366.7% |
| 2026-02-23 | $0.14 | $0.11 | +27.3% |
| 2025-10-28 | $0.49 | $0.28 | +75.0% |
| 2025-07-29 | $0.50 | $0.10 | +400.0% |
| 2025-04-30 | $0.28 | $0.11 | +154.5% |
| 2025-02-18 | $0.70 | $0.04 | +1650.0% |
Valuation Ratios
| Price / Book | 8.89 |
| EV / EBITDA | -29.92 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $196.2M | $179.3M | $212.2M | $234.7M | $202.6M | $305.4M | $427.5M |
| Cost of Revenue | $113.4M | $175.3M | $228.8M | $261.4M | $112.6M | $111.1M | $129.4M |
| Gross Profit | $82.8M | $4.0M | -$16.6M | -$26.8M | $90.0M | $194.4M | $298.2M |
| Research & Development | $34.9M | $72.7M | $105.2M | $86.2M | $58.3M | $45.7M | $72.0M |
| Selling, General & Admin | $68.8M | $163.9M | $318.7M | $338.2M | $194.7M | $168.5M | $239.2M |
| Operating Expenses | $113.2M | $246.0M | $429.5M | $640.9M | $270.6M | $217.6M | $311.2M |
| Operating Income | -$30.4M | -$242.0M | -$446.1M | -$667.7M | -$180.6M | -$23.2M | -$11.8M |
| EBITDA | -$22.5M | -$227.1M | -$220.7M | -$398.2M | -$136.5M | -$27.6M | $6.6M |
| Interest Expense | $783,000 | $2.5M | $2.8M | $3.2M | 0 | $3.0M | $2.5M |
| Pre-tax Income | -$29.7M | -$241.3M | -$245.4M | -$598.0M | -$176.7M | -$52.6M | -$21.1M |
| Income Tax | 0 | 0 | 0 | -$49.1M | -$926,000 | -$343,000 | -$116,000 |
| Net Income | -$29.7M | -$241.3M | -$245.4M | -$549.0M | -$175.8M | -$52.3M | -$21.0M |
| EPS | $-4.26 | $-33.16 | $-74.93 | $-53.63 | $-7.23 | $-1.94 | $-0.73 |
| EPS (Diluted) | $-18.48 | $-146.94 | $-74.93 | $-53.63 | $-7.23 | $-1.94 | $-0.73 |
| Shares Outstanding (Diluted) | $5.6M | $5.6M | $3.3M | $10.2M | $24.3M | $26.9M | $26.9M |
Price
| Price | $76.27 |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Related companies: HNGE · IMVT · KYMR · NAMS · OPCH · OSCR
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of WGS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks